NCT05645536: An ongoing trial by Tolmar Inc.
This trial is ongoing. It must report results 3 years, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05645536 |
|---|---|
| Title | Open-label, Safety Extension Study for Subjects With HR+, HER2-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer OVELIA Study |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 28, 2022 |
| Completion date | June 30, 2028 |
| Required reporting date | June 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |